1
|
Li N, Chen Z, Zhan Y, Deng W, Lv T, Xu Z, Wang L, Liu B. Anti-cancer drug axitinib: a unique tautomerism-induced dual-emissive probe for protein analysis. Chem Commun (Camb) 2024; 60:6138-6141. [PMID: 38804199 DOI: 10.1039/d4cc01944j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2024]
Abstract
A commercial anti-cancer drug, axitinib, exhibits very stable dual emissions for discrimination of human serum albumin.
Collapse
Affiliation(s)
- Na Li
- College of Material Science and Engineering, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, Shenzhen University, Shenzhen 518060, PR China.
| | - Zihao Chen
- College of Material Science and Engineering, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, Shenzhen University, Shenzhen 518060, PR China.
| | - Yilin Zhan
- College of Material Science and Engineering, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, Shenzhen University, Shenzhen 518060, PR China.
| | - Weihua Deng
- College of Material Science and Engineering, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, Shenzhen University, Shenzhen 518060, PR China.
| | - Taoyuze Lv
- School of Physics, The University of Sydney, NSW 2006, Australia
| | - Zhongyong Xu
- College of Material Science and Engineering, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, Shenzhen University, Shenzhen 518060, PR China.
| | - Lei Wang
- College of Material Science and Engineering, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, Shenzhen University, Shenzhen 518060, PR China.
| | - Bin Liu
- College of Material Science and Engineering, Guangdong Provincial Key Laboratory of New Energy Materials Service Safety, Shenzhen University, Shenzhen 518060, PR China.
| |
Collapse
|
2
|
Breton-Patient C, Billotte S, Duchambon P, Fontaine G, Bombard S, Piguel S. Light-Activatable Photocaged UNC2025 for Triggering TAM Kinase Inhibition in Bladder Cancer. Chembiochem 2024; 25:e202300855. [PMID: 38363151 DOI: 10.1002/cbic.202300855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 02/15/2024] [Accepted: 02/16/2024] [Indexed: 02/17/2024]
Abstract
Photopharmacology is an emerging field that utilizes photo-responsive molecules to enable control over the activity of a drug using light. The aim is to limit the therapeutic action of a drug at the level of diseased tissues and organs. Considering the well-known implications of protein kinases in cancer and the therapeutic issues associated with protein kinase inhibitors, the photopharmacology is seen as an innovative and alternative solution with great potential in oncology. In this context, we developed the first photocaged TAM kinase inhibitors based on UNC2025, a first-in-class small molecule kinase inhibitor. These prodrugs showed good stability in biologically relevant buffer and rapid photorelease of the photoremovable protecting group upon UV-light irradiation (<10 min.). These light-activatable prodrugs led to a 16-fold decrease to a complete loss of kinase inhibition, depending on the protein and the position at which the coumarin-type phototrigger was introduced. The most promising candidate was the N,O-dicaged compound, showing the superiority of having two photolabile protecting groups on UNC2025 for being entirely inactive on TAM kinases. Under UV-light irradiation, the N,O-dicaged compound recovered its inhibitory potency in enzymatic assays and displayed excellent antiproliferative activity in RT112 cell lines.
Collapse
Affiliation(s)
- Chloé Breton-Patient
- Institut Curie, Université PSL CNRS UMR9187, Inserm U119, 91400, Orsay, France
- Université Paris-Saclay CNRS UMR9187, Inserm U119, 91400, Orsay, France
| | - Sébastien Billotte
- Université Paris-Saclay, Faculté de Pharmacie CNRS UMR 8076, 91400, Orsay, France
| | - Patricia Duchambon
- Institut Curie, Université PSL CNRS UMR9187, Inserm U119, 91400, Orsay, France
- Université Paris-Saclay CNRS UMR9187, Inserm U119, 91400, Orsay, France
| | - Gaëlle Fontaine
- Institut Curie, Université PSL CNRS UMR9187, Inserm U119, 91400, Orsay, France
- Université Paris-Saclay CNRS UMR9187, Inserm U119, 91400, Orsay, France
| | - Sophie Bombard
- Institut Curie, Université PSL CNRS UMR9187, Inserm U119, 91400, Orsay, France
- Université Paris-Saclay CNRS UMR9187, Inserm U119, 91400, Orsay, France
| | - Sandrine Piguel
- Université Paris-Saclay, Faculté de Pharmacie CNRS UMR 8076, 91400, Orsay, France
| |
Collapse
|
3
|
Dumazer A, Gómez-Santacana X, Malhaire F, Jopling C, Maurel D, Lebon G, Llebaria A, Goudet C. Optical Control of Adenosine A 2A Receptor Using Istradefylline Photosensitivity. ACS Chem Neurosci 2024; 15:645-655. [PMID: 38275568 DOI: 10.1021/acschemneuro.3c00721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2024] Open
Abstract
In recent years, there has been growing interest in the potential therapeutic use of inhibitors of adenosine A2A receptors (A2AR) for the treatment of neurodegenerative diseases and cancer. Nevertheless, the widespread expression of A2AR throughout the body emphasizes the importance of temporally and spatially selective ligands. Photopharmacology is an emerging strategy that utilizes photosensitive ligands to attain high spatiotemporal precision and regulate the function of biomolecules using light. In this study, we combined photochemistry and cellular and in vivo photopharmacology to investigate the light sensitivity of the FDA-approved antagonist istradefylline and its potential use as an A2AR photopharmacological tool. Our findings reveal that istradefylline exhibits rapid trans-to-cis isomerization under near-UV light, and prolonged exposure results in the formation of photocycloaddition products. We demonstrate that exposure to UV light triggers a time-dependent decrease in the antagonistic activity of istradefylline in A2AR-expressing cells and enables real-time optical control of A2AR signaling in living cells and zebrafish. Together, these data demonstrate that istradefylline is a photoinactivatable A2AR antagonist and that this property can be utilized to perform photopharmacological experiments in living cells and animals.
Collapse
Affiliation(s)
- Anaëlle Dumazer
- IGF, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France
- MCS, Laboratory of Medicinal Chemistry and Synthesis, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain
| | - Xavier Gómez-Santacana
- MCS, Laboratory of Medicinal Chemistry and Synthesis, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain
| | - Fanny Malhaire
- IGF, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France
| | - Chris Jopling
- IGF, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France
| | - Damien Maurel
- IGF, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France
| | - Guillaume Lebon
- IGF, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France
| | - Amadeu Llebaria
- MCS, Laboratory of Medicinal Chemistry and Synthesis, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain
| | - Cyril Goudet
- IGF, Université de Montpellier, CNRS, INSERM, 34094 Montpellier, France
| |
Collapse
|
4
|
Zhang Z, Le GNT, Ge Y, Tang X, Chen X, Ejim L, Bordeleau E, Wright GD, Burns DC, Tran S, Axerio-Cilies P, Wang YT, Dong M, Woolley GA. Isomerization of bioactive acylhydrazones triggered by light or thiols. Nat Chem 2023; 15:1285-1295. [PMID: 37308709 DOI: 10.1038/s41557-023-01239-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 05/12/2023] [Indexed: 06/14/2023]
Abstract
The acylhydrazone unit is well represented in screening databases used to find ligands for biological targets, and numerous bioactive acylhydrazones have been reported. However, potential E/Z isomerization of the C=N bond in these compounds is rarely examined when bioactivity is assayed. Here we analysed two ortho-hydroxylated acylhydrazones discovered in a virtual drug screen for modulators of N-methyl-D-aspartate receptors and other bioactive hydroxylated acylhydrazones with structurally defined targets reported in the Protein Data Bank. We found that ionized forms of these compounds, which are populated under laboratory conditions, photoisomerize readily and the isomeric forms have markedly different bioactivity. Furthermore, we show that glutathione, a tripeptide involved with cellular redox balance, catalyses dynamic E⇄Z isomerization of acylhydrazones. The ratio of E to Z isomers in cells is determined by the relative stabilities of the isomers regardless of which isomer was applied. We conclude that E/Z isomerization may be a common feature of the bioactivity observed with acylhydrazones and should be routinely analysed.
Collapse
Affiliation(s)
- Zhiwei Zhang
- Department of Chemistry, University of Toronto, Toronto, Ontario, Canada
- Key Laboratory for Advanced Materials, School of Chemistry and Molecular Engineering, East China University of Science and Technology, Shanghai, China
| | - Giang N T Le
- Department of Chemistry, University of Toronto, Toronto, Ontario, Canada
| | - Yang Ge
- Department of Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - Xiaowen Tang
- Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China
| | - Xin Chen
- Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China
| | - Linda Ejim
- David Braley Centre for Antibiotics Discovery M.G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
| | - Emily Bordeleau
- David Braley Centre for Antibiotics Discovery M.G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
| | - Gerard D Wright
- David Braley Centre for Antibiotics Discovery M.G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
| | - Darcy C Burns
- Department of Chemistry, University of Toronto, Toronto, Ontario, Canada
| | - Susannah Tran
- Department of Chemistry, University of Toronto, Toronto, Ontario, Canada
| | - Peter Axerio-Cilies
- Department of Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.
| | - Yu Tian Wang
- Department of Medicine, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.
| | - Mingxin Dong
- Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, China.
| | - G Andrew Woolley
- Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
5
|
Aguirre T, Teichmann E, Römpp FQ, Vivier R, Bryant C, Hulverson MA, Van Voorhis WC, Ojo KK, Doggett JS, Fiedler D, Hecht S. Photoswitchable Inhibitors to Optically Control Specific Kinase Activity. ACS Chem Biol 2023; 18:1378-1387. [PMID: 37167414 DOI: 10.1021/acschembio.3c00119] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Potent and selective small-molecule inhibitors are valuable tools to elucidate the functions of protein kinases within complex signaling networks. Incorporation of a photoswitchable moiety into the inhibitor scaffold offers the opportunity to steer inhibitor potency with temporal precision, while the challenge of selective inhibition can often be addressed by employing a chemical genetic approach, termed the analog-sensitive method. Here, we combine the perks of these two approaches and report photoswitchable azopyrazoles to target calcium-dependent protein kinase 1 (CDPK1) from Toxoplasma gondii, a kinase naturally susceptible to analog-sensitive kinase inhibitors due to its glycine gatekeeper residue. The most promising azopyrazoles display favorable photochemical properties, thermal stability, and a substantial difference in IC50 values between both photostationary states. Consequently, the CDPK1 kinase reaction can be controlled dynamically and reversibly by applying light of different wavelengths. Inhibition of CDPK1 by the azopyrazoles drastically relies on the nature of the gatekeeper residue as a successive increase in gatekeeper size causes a concurrent loss of inhibitory activity. Furthermore, two photoswitchable inhibitors exhibit activity against T. gondii and Cryptosporidium parvum infection in a cell culture model, making them a promising addition to the toolbox for dissecting the role of CDPK1 in the infectious cycle with high temporal control. Overall, this work merges the benefits of the analog-sensitive approach and photopharmacology without compromising inhibitory potency and thus holds great promise for application to other protein kinases in the future.
Collapse
Affiliation(s)
- Tim Aguirre
- Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Straße 10, 13125 Berlin, Germany
| | - Ellen Teichmann
- Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany
| | - Florian Q Römpp
- Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany
- DWI-Leibniz Institute for Interactive Materials, Forckenbeckstr. 50, 52074 Aachen, Germany
- Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Worringer Weg 2, 52074 Aachen, Germany
| | - Ruthey Vivier
- VA Portland Healthcare System, Portland, 97239 Oregon, United States
- School of Medicine Division of Infectious Diseases, Oregon Health & Science University, Portland, 97239 Oregon, United States
| | - Cole Bryant
- VA Portland Healthcare System, Portland, 97239 Oregon, United States
- School of Medicine Division of Infectious Diseases, Oregon Health & Science University, Portland, 97239 Oregon, United States
| | - Matthew A Hulverson
- Division of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, University of Washington, 750 Republican Street, P.O. Box 358061, Seattle, 98109 Washington, United States
| | - Wesley C Van Voorhis
- Division of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, University of Washington, 750 Republican Street, P.O. Box 358061, Seattle, 98109 Washington, United States
| | - Kayode K Ojo
- Division of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, University of Washington, 750 Republican Street, P.O. Box 358061, Seattle, 98109 Washington, United States
| | - J Stone Doggett
- VA Portland Healthcare System, Portland, 97239 Oregon, United States
- School of Medicine Division of Infectious Diseases, Oregon Health & Science University, Portland, 97239 Oregon, United States
| | - Dorothea Fiedler
- Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Robert-Rössle-Straße 10, 13125 Berlin, Germany
| | - Stefan Hecht
- Department of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany
| |
Collapse
|
6
|
Scherbakov A, Zakharov AV, Mikhaevich EI, Salnikova DI, Yadykov AV, Kozhevnikova AA, Shirinian VZ. Photostability and Antiproliferative Activity of Furan Analogues of Combretastatin A-4. Chem Res Toxicol 2022; 35:2014-2024. [PMID: 36084334 DOI: 10.1021/acs.chemrestox.2c00204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Cancer is one of the most serious health problems that usually require heavy medical treatment. It is important to ensure that no additional burden is placed on patients due to the modes of administration and/or poor quality of pharmaceuticals. In this regard, understanding, quantifying, and improving the photostability (resistance to UV light or sunlight) of drugs is among the important elements that can improve the patient's quality of life. In this work, the photochemical properties of a wide range of furanone analogues of combretastatin A-4 and their antiproliferative activity against A-431 epidermoid carcinoma cells were studied in a search for compounds with improved photostability and antiproliferative activity. It was found that the incorporation of an arylidene moiety led to a significant improvement in photostability, while the antiproliferative activity strongly depends on the nature of the aryl residue in the arylidene moiety. The high photostability of arylidenes was achieved due to the delocalization of the central double bond of the 1,3,5-hexatriene system, which limited the 6π-electrocyclization. The best results in terms of antiproliferative activity were obtained for thiophene arylidene (IC50 = 0.6 μM) and 3,4-diarylfuran (IC50 = 0.047 μM). The obtained results address the lack of data available now in scientific literature on the photodegradation of combretastatin A-4 analogues and should be taken into account in studies of the side effects of pharmaceuticals based on them.
Collapse
Affiliation(s)
- Alexander Scherbakov
- N. N. Blokhin National Medical Research Center of Oncology, Kashirskoye sh. 24, 115522 Moscow, Russian Federation
| | - Alexey V Zakharov
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow 119991, Russian Federation
| | - Ekaterina I Mikhaevich
- N. N. Blokhin National Medical Research Center of Oncology, Kashirskoye sh. 24, 115522 Moscow, Russian Federation
| | - Diana I Salnikova
- N. N. Blokhin National Medical Research Center of Oncology, Kashirskoye sh. 24, 115522 Moscow, Russian Federation
| | - Anton V Yadykov
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow 119991, Russian Federation
| | - Arina A Kozhevnikova
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow 119991, Russian Federation
| | - Valerii Z Shirinian
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow 119991, Russian Federation
| |
Collapse
|
7
|
Hemipiperazines as peptide-derived molecular photoswitches with low-nanomolar cytotoxicity. Nat Commun 2022; 13:6066. [PMID: 36241620 PMCID: PMC9568564 DOI: 10.1038/s41467-022-33750-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 09/30/2022] [Indexed: 12/24/2022] Open
Abstract
Molecular photoswitches transform light energy into reversible structural changes. Their combination with known pharmacophores often allows for photomodulation of the biological activity. The effort to apply such compounds in photopharmacology as light-activated pro-drugs is, however, hampered by serious activity reduction upon pharmacophore modifications, or limited biostability. Here we report that a potent antimitotic agent plinabulin and its derivatives demonstrate up to 56-fold reversible activity photomodulation. Alternatively, irreversible photoactivation with cyan light can enhance the cytotoxicity up to three orders of magnitude-all without compromising the original activity level, as the original pharmacophore structure is unchanged. This occurs due to the presence of a peptide-derived photoswitchable motif hemipiperazine inside the plinabulin scaffold. Furthermore, we systematically describe photochromism of these thermally stable and biocompatible hemipiperazines, as well as a photoswitchable fluorophore derived from plinabulin. The latter may further expand the applicability of hemipiperazine photochromism towards super-resolution microscopy.
Collapse
|
8
|
Schulte AM, Kolarski D, Sundaram V, Srivastava A, Tama F, Feringa BL, Szymanski W. Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors. Int J Mol Sci 2022; 23:ijms23105326. [PMID: 35628143 PMCID: PMC9140716 DOI: 10.3390/ijms23105326] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 05/05/2022] [Accepted: 05/07/2022] [Indexed: 02/04/2023] Open
Abstract
Protein kinases are responsible for healthy cellular processes and signalling pathways, and their dysfunction is the basis of many pathologies. There are numerous small molecule inhibitors of protein kinases that systemically regulate dysfunctional signalling processes. However, attaining selectivity in kinase inhibition within the complex human kinome is still a challenge that inspires unconventional approaches. One of those approaches is photopharmacology, which uses light-controlled bioactive molecules to selectively activate drugs only at the intended space and time, thereby avoiding side effects outside of the irradiated area. Still, in the context of kinase inhibition, photopharmacology has thus far been rather unsuccessful in providing light-controlled drugs. Here, we present the discovery and optimisation of a photoswitchable inhibitor of casein kinase 1δ (CK1δ), important for the control of cell differentiation, circadian rhythm, DNA repair, apoptosis, and numerous other signalling processes. Varying the position at which the light-responsive azobenzene moiety has been introduced into a known CK1δ inhibitor, LH846, revealed the preferred regioisomer for efficient photo-modulation of inhibitory activity, but the photoswitchable inhibitor suffered from sub-optimal (photo)chemical properties. Replacement of the bis-phenyl azobenzene group with the arylazopyrazole moiety yielded a superior photoswitch with very high photostationary state distributions, increased solubility and a 10-fold difference in activity between irradiated and thermally adapted samples. The reasons behind those findings are explored with molecular docking and molecular dynamics simulations. Results described here show how the evaluation of privileged molecular architecture, followed by the optimisation of the photoswitchable unit, is a valuable strategy for the challenging design of the photoswitchable kinase inhibitors.
Collapse
Affiliation(s)
- Albert M. Schulte
- Stratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands; (A.M.S.); (D.K.)
| | - Dušan Kolarski
- Stratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands; (A.M.S.); (D.K.)
| | - Vidya Sundaram
- Discipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar 382355, India; (V.S.); (A.S.)
| | - Ashutosh Srivastava
- Discipline of Biological Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar 382355, India; (V.S.); (A.S.)
| | - Florence Tama
- Institute of Transformative BioMolecules (WPI-ITbM), Nagoya University, Chikusa, Nagoya 464-8601, Japan;
- Department of Physics, Graduate School of Science, Nagoya University, Chikusa, Nagoya 464-8602, Japan
- Computational Structural Biology Unit, RIKEN-Center for Computational Science, Chuo, Kobe 650-0047, Japan
| | - Ben L. Feringa
- Stratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands; (A.M.S.); (D.K.)
- Correspondence: (B.L.F.); (W.S.)
| | - Wiktor Szymanski
- Stratingh Institute for Chemistry, University of Groningen, 9747 AG Groningen, The Netherlands; (A.M.S.); (D.K.)
- Department of Radiology, Medical Imaging Center, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
- Correspondence: (B.L.F.); (W.S.)
| |
Collapse
|
9
|
Xu Y, Gao C, Andreasson M, Håversen L, Carrasco M, Fleming C, Lundbäck T, Andréasson J, Grøtli M. Design and development of photoswitchable DFG-Out RET kinase inhibitors. Eur J Med Chem 2022; 234:114226. [DOI: 10.1016/j.ejmech.2022.114226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 02/04/2022] [Accepted: 02/21/2022] [Indexed: 11/04/2022]
|
10
|
Davighi MG, Clemente F, Matassini C, Cardona F, Nielsen MB, Goti A, Morrone A, Paoli P, Cacciarini M. Photoswitchable inhibitors of human β-glucocerebrosidase. Org Biomol Chem 2022; 20:1637-1641. [PMID: 35107482 DOI: 10.1039/d1ob02159a] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Light-switchable inhibitors of the enzyme β-glucocerebrosidase (GCase) have been developed by anchoring a specific azasugar to a dihydroazulene or an azobenzene responsive moiety. Their inhibitory effect towards human GCase, before and after irradiation are reported, and the effect on thermal denaturation of recombinant GCase and cytotoxicity were studied on selected candidates.
Collapse
Affiliation(s)
- Maria Giulia Davighi
- Department of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3-13, 50019 Sesto F.no (FI), Italy.
| | - Francesca Clemente
- Department of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3-13, 50019 Sesto F.no (FI), Italy.
| | - Camilla Matassini
- Department of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3-13, 50019 Sesto F.no (FI), Italy.
| | - Francesca Cardona
- Department of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3-13, 50019 Sesto F.no (FI), Italy. .,Associated with LENS, via N. Carrara 1, 50019 Sesto F.no (FI), Italy
| | - Mogens Brøndsted Nielsen
- Department of Chemistry, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen Ø, Denmark
| | - Andrea Goti
- Department of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3-13, 50019 Sesto F.no (FI), Italy. .,Associated with LENS, via N. Carrara 1, 50019 Sesto F.no (FI), Italy
| | - Amelia Morrone
- Paediatric Neurology Unit and Laboratories, Neuroscience Department, Meyer Children's Hospital, and Department of Neurosciences, Pharmacology and Child Health. University of Florence, Viale Pieraccini 24, 50139 Firenze, Italy
| | - Paolo Paoli
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134 Firenze, Italy
| | - Martina Cacciarini
- Department of Chemistry "U. Schiff", University of Florence, via della Lastruccia 3-13, 50019 Sesto F.no (FI), Italy.
| |
Collapse
|
11
|
Juengel E, Schnalke P, Rutz J, Maxeiner S, Chun FKH, Blaheta RA. Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment. Biomedicines 2021; 9:biomedicines9111630. [PMID: 34829859 PMCID: PMC8615644 DOI: 10.3390/biomedicines9111630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Revised: 11/01/2021] [Accepted: 11/04/2021] [Indexed: 12/24/2022] Open
Abstract
Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy has not yet been established. The present investigation is directed towards comparing the anti-angiogenic properties of the TKIs, sorafenib and axitinib on human endothelial cells (HUVECs) with acquired resistance towards the TKI sunitinib. HUVECs were driven to resistance by continuously exposing them to sunitinib for six weeks. They were then switched to a 24 h or further six weeks treatment with sorafenib or axitinib. HUVEC growth, as well as angiogenesis (tube formation and scratch wound assay), were evaluated. Cell cycle proteins of the CDK-cyclin axis (CDK1 and 2, total and phosphorylated, cyclin A and B) and the mTOR pathway (AKT, total and phosphorylated) were also assessed. Axitinib (but not sorafenib) significantly suppressed growth of sunitinib-resistant HUVECs when they were exposed for six weeks. This axinitib-associated growth reduction was accompanied by a cell cycle block at the G0/G1-phase. Both axitinib and sorafenib reduced HUVEC tube length and prevented wound closure (sorafenib > axitinib) when applied to sunitinib-resistant HUVECs for six weeks. Protein analysis revealed diminished phosphorylation of CDK1, CDK2 and pAKT, accompanied by a suppression of cyclin A and B. Both drugs modulated CDK-cyclin and AKT-dependent signaling, associated either with both HUVEC growth and angiogenesis (axitinib) or angiogenesis alone (sorafenib). Axitinib and sorafenib may be equally applicable as second line treatment options, following sunitinib resistance.
Collapse
Affiliation(s)
- Eva Juengel
- Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany; (E.J.); (P.S.); (J.R.); (S.M.); (F.K.-H.C.)
- Department of Urology and Pediatric Urology, University Medical Center Mainz, 55131 Mainz, Germany
| | - Pascal Schnalke
- Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany; (E.J.); (P.S.); (J.R.); (S.M.); (F.K.-H.C.)
| | - Jochen Rutz
- Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany; (E.J.); (P.S.); (J.R.); (S.M.); (F.K.-H.C.)
| | - Sebastian Maxeiner
- Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany; (E.J.); (P.S.); (J.R.); (S.M.); (F.K.-H.C.)
| | - Felix K.-H. Chun
- Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany; (E.J.); (P.S.); (J.R.); (S.M.); (F.K.-H.C.)
| | - Roman A. Blaheta
- Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany; (E.J.); (P.S.); (J.R.); (S.M.); (F.K.-H.C.)
- Correspondence:
| |
Collapse
|
12
|
Mansour MA, Caputo VS, Aleem E. Highlights on selected growth factors and their receptors as promising anticancer drug targets. Int J Biochem Cell Biol 2021; 140:106087. [PMID: 34563698 DOI: 10.1016/j.biocel.2021.106087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Revised: 09/16/2021] [Accepted: 09/20/2021] [Indexed: 10/20/2022]
Abstract
Growth factor receptors (GFRs) and receptor tyrosine kinases (RTK) are groups of proteins mediating a plethora of physiological processes, including cell growth, proliferation, survival, differentiation and migration. Under certain circumstances, expression of GFRs and subsequently their downstream kinase signaling are deregulated by genetic, epigenetic, and somatic changes leading to uncontrolled cell division in many human diseases, most notably cancer. Cancer cells rely on growth factors to sustain the increasing need to cell division and metabolic reprogramming through cancer-associated activating mutations of their receptors (i.e., GFRs). In this review, we highlight the recent advances of selected GFRs and their ligands (growth factors) in cancer with emphasis on structural and functional differences. We also interrogate how overexpression and/or hyperactivation of GFRs contribute to cancer initiation, development, progression, and resistance to conventional chemo- and radiotherapies. Novel approaches are being developed as anticancer agents to target growth factor receptors and their signaling pathways in different cancers. Here, we illustrate how the current knowledge of GFRs biology, and their ligands lead to development of targeted therapies to inhibit and/or block the activity of growth factors, GFRs and downstream kinases to treat diseases such as cancer.
Collapse
Affiliation(s)
- Mohammed A Mansour
- Cancer Biology and Therapy Lab, Division of Human Sciences, School of Applied Sciences, London South Bank University, London, UK; Biochemistry Division, Department of Chemistry, Faculty of Science, Tanta University, Tanta 31527, Egypt.
| | - Valentina S Caputo
- Cancer Biology and Therapy Lab, Division of Human Sciences, School of Applied Sciences, London South Bank University, London, UK
| | - Eiman Aleem
- Cancer Biology and Therapy Lab, Division of Human Sciences, School of Applied Sciences, London South Bank University, London, UK.
| |
Collapse
|
13
|
Reynders M, Chaikuad A, Berger B, Bauer K, Koch P, Laufer S, Knapp S, Trauner D. Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202103767] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Martin Reynders
- Department of Chemistry, Silver Center for Arts and Science New York University 100 Washington Square East New York NY 10003 USA
- Department of Chemistry Ludwig Maximilians University of Munich Butenandtstr.5–13 81377 Munich Germany
| | - Apirat Chaikuad
- Buchmann Institute for Molecular Life Sciences Johann Wolfgang Goethe-University 60438 Frankfurt am Main Germany
- Institute for Pharmaceutical Chemistry Johann Wolfgang Goethe-University 60438 Frankfurt am Main Germany
- Structural Genomics Consortium Frankfurt 60438 Frankfurt am Main Germany
| | - Benedict‐Tilman Berger
- Buchmann Institute for Molecular Life Sciences Johann Wolfgang Goethe-University 60438 Frankfurt am Main Germany
- Institute for Pharmaceutical Chemistry Johann Wolfgang Goethe-University 60438 Frankfurt am Main Germany
- Structural Genomics Consortium Frankfurt 60438 Frankfurt am Main Germany
| | - Katharina Bauer
- Department of Pharmaceutical/ Medicinal Chemistry Eberhard-Karls-University Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
- Tuebingen Center for Academic Drug Discovery Germany
| | - Pierre Koch
- Department of Pharmaceutical/ Medicinal Chemistry Eberhard-Karls-University Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
- Tuebingen Center for Academic Drug Discovery Germany
- Department of Pharmaceutical/Medicinal Chemistry II Institute of Pharmacy University of Regensburg 93040 Regensburg Germany
| | - Stefan Laufer
- Department of Pharmaceutical/ Medicinal Chemistry Eberhard-Karls-University Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
- Tuebingen Center for Academic Drug Discovery Germany
| | - Stefan Knapp
- Buchmann Institute for Molecular Life Sciences Johann Wolfgang Goethe-University 60438 Frankfurt am Main Germany
- Institute for Pharmaceutical Chemistry Johann Wolfgang Goethe-University 60438 Frankfurt am Main Germany
- Structural Genomics Consortium Frankfurt 60438 Frankfurt am Main Germany
- German Cancer Network (DKTK) Frankfurt/Mainz site 60438 Frankfurt am Main Germany
| | - Dirk Trauner
- Department of Chemistry, Silver Center for Arts and Science New York University 100 Washington Square East New York NY 10003 USA
| |
Collapse
|
14
|
Reynders M, Chaikuad A, Berger BT, Bauer K, Koch P, Laufer S, Knapp S, Trauner D. Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. Angew Chem Int Ed Engl 2021; 60:20178-20183. [PMID: 34081840 PMCID: PMC9940781 DOI: 10.1002/anie.202103767] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 05/23/2021] [Indexed: 12/14/2022]
Abstract
Covalent kinase inhibitors account for some of the most successful drugs that have recently entered the clinic and many others are in preclinical development. A common strategy is to target cysteines in the vicinity of the ATP binding site using an acrylamide electrophile. To increase the tissue selectivity of kinase inhibitors, it could be advantageous to control the reactivity of these electrophiles with light. Here, we introduce covalent inhibitors of the kinase JNK3 that function as photoswitchable affinity labels (PALs). Our lead compounds contain a diazocine photoswitch, are poor non-covalent inhibitors in the dark, and become effective covalent inhibitors after irradiation with visible light. Our proposed mode of action is supported by X-ray structures that explain why these compounds are unreactive in the dark and undergo proximity-based covalent attachment following exposure to light.
Collapse
Affiliation(s)
- Martin Reynders
- Department of Chemistry, Silver Center for Arts and Science, New York University 100 Washington Square East, New York, NY 10003 (USA),Department of Chemistry, Ludwig Maximilians University of Munich Butenandtstr.5–13, 81377 Munich (Germany)
| | - Apirat Chaikuad
- Buchmann Institute for Molecular Life Sciences Johann Wolfgang Goethe-University 60438 Frankfurt am Main (Germany) and Institute for Pharmaceutical Chemistry Johann Wolfgang Goethe-University 60438 Frankfurt am Main (Germany) and Structural Genomics Consortium Frankfurt 60438 Frankfurt am Main (Germany)
| | - Benedict-Tilman Berger
- Buchmann Institute for Molecular Life Sciences Johann Wolfgang Goethe-University 60438 Frankfurt am Main (Germany) and Institute for Pharmaceutical Chemistry Johann Wolfgang Goethe-University 60438 Frankfurt am Main (Germany) and Structural Genomics Consortium Frankfurt 60438 Frankfurt am Main (Germany)
| | - Katharina Bauer
- Department of Pharmaceutical / Medicinal Chemistry, Eberhard-Karls-University Tübingen, Auf der Morgenstelle 8, D-72076 Tübingen (Germany) and Tuebingen Center for Academic Drug Discovery
| | - Pierre Koch
- Buchmann Institute for Molecular Life Sciences Johann Wolfgang Goethe-University 60438 Frankfurt am Main (Germany) and Institute for Pharmaceutical Chemistry Johann Wolfgang Goethe-University 60438 Frankfurt am Main (Germany) and Structural Genomics Consortium Frankfurt 60438 Frankfurt am Main (Germany),Department of Pharmaceutical / Medicinal Chemistry, Eberhard-Karls-University Tübingen, Auf der Morgenstelle 8, D-72076 Tübingen (Germany) and Tuebingen Center for Academic Drug Discovery
| | - Stefan Laufer
- Department of Pharmaceutical / Medicinal Chemistry, Eberhard-Karls-University Tübingen, Auf der Morgenstelle 8, D-72076 Tübingen (Germany) and Tuebingen Center for Academic Drug Discovery
| | - Stefan Knapp
- Buchmann Institute for Molecular Life Sciences Johann Wolfgang Goethe-University 60438 Frankfurt am Main (Germany) and Institute for Pharmaceutical Chemistry Johann Wolfgang Goethe-University 60438 Frankfurt am Main (Germany) and Structural Genomics Consortium Frankfurt 60438 Frankfurt am Main (Germany),German Cancer Network (DKTK), Frankfurt/Mainz site 60438 Frankfurt am Main (Germany)
| | - Dirk Trauner
- Department of Chemistry, Silver Center for Arts and Science, New York University 100 Washington Square East, New York, NY 10003 (USA)
| |
Collapse
|
15
|
Photopharmacological Applications for Cherenkov Radiation Generated by Clinically Used Radionuclides. Int J Mol Sci 2021; 22:ijms22169010. [PMID: 34445716 PMCID: PMC8396513 DOI: 10.3390/ijms22169010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Revised: 08/16/2021] [Accepted: 08/17/2021] [Indexed: 01/10/2023] Open
Abstract
Translational photopharmacological applications are limited through irradiation by light showing wavelengths within the bio-optical window. To achieve sufficient tissue penetration, using wavelengths >500 nm is mandatory. Nevertheless, the majority of photopharmacological compounds respond to irradiation with more energetic UV light, which shows only a minor depth of tissue penetration in the µm range. Thus, we became interested in UV light containing Cherenkov radiation (CR) induced as a by-product by clinically employed radionuclides labeling specific tissues. Therefore, CR may be applicable in novel photopharmacological approaches. To provide evidence for the hypothesis, we verified the clinically established radionuclides 68Ga and 90Y but not 18F in clinically used activities to be capable of generating CR in aqueous solutions. We then investigated whether the generated CR was able to photoactivate the caged kinase inhibitor cagedAZD5438 as a photoresponsive model system. Herein, 21% uncaging of the model system cagedAZD5438 occurred by incubation with 90Y, along with a non-specific compound decomposition for 68Ga and partly for 90Y. The findings suggest that the combination of a clinically employed radionuclide with an optimized photoresponsive agent could be beneficial for highly focused photopharmacological therapies.
Collapse
|
16
|
Le Bescont J, Mouawad L, Boddaert T, Bombard S, Piguel S. Photoactivatable Small‐Molecule Inhibitors for Light‐Controlled TAM Kinase Activity. CHEMPHOTOCHEM 2021. [DOI: 10.1002/cptc.202100131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Julie Le Bescont
- Institut Curie Université PSL CNRS UMR 9187 INSERM U1196 Chimie et Modélisation pour la Biologie du Cancer 91405 Orsay France
- Université Paris-Saclay CNRS UMR 9187 INSERM U1196 Chimie et Modélisation pour la Biologie du Cancer 91405 Orsay France
| | - Liliane Mouawad
- Institut Curie Université PSL CNRS UMR 9187 INSERM U1196 Chimie et Modélisation pour la Biologie du Cancer 91405 Orsay France
- Université Paris-Saclay CNRS UMR 9187 INSERM U1196 Chimie et Modélisation pour la Biologie du Cancer 91405 Orsay France
| | - Thomas Boddaert
- Université Paris-Saclay CNRS UMR 8182 ICMMO CP3A Organic Synthesis Group 91405 Orsay France
| | - Sophie Bombard
- Institut Curie Université PSL CNRS UMR 9187 INSERM U1196 Chimie et Modélisation pour la Biologie du Cancer 91405 Orsay France
- Université Paris-Saclay CNRS UMR 9187 INSERM U1196 Chimie et Modélisation pour la Biologie du Cancer 91405 Orsay France
| | - Sandrine Piguel
- Institut Curie Université PSL CNRS UMR 9187 INSERM U1196 Chimie et Modélisation pour la Biologie du Cancer 91405 Orsay France
- Université Paris-Saclay CNRS UMR 9187 INSERM U1196 Chimie et Modélisation pour la Biologie du Cancer 91405 Orsay France
| |
Collapse
|
17
|
Strizhak AV, Babii O, Afonin S, Bakanovich I, Pantelejevs T, Xu W, Fowler E, Eapen R, Sharma K, Platonov MO, Hurmach VV, Itzhaki L, Hyvönen M, Ulrich AS, Spring DR, Komarov IV. Diarylethene moiety as an enthalpy-entropy switch: photoisomerizable stapled peptides for modulating p53/MDM2 interaction. Org Biomol Chem 2021; 18:5359-5369. [PMID: 32390036 DOI: 10.1039/d0ob00831a] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Analogs of the known inhibitor (peptide pDI) of the p53/MDM2 protein-protein interaction are reported, which are stapled by linkers bearing a photoisomerizable diarylethene moiety. The corresponding photoisomers possess significantly different affinities to the p53-interacting domain of the human MDM2. Apparent dissociation constants are in the picomolar-to-low nanomolar range for those isomers with diarylethene in the "open" configuration, but up to eight times larger for the corresponding "closed" isomers. Spectroscopic, structural, and computational studies showed that the stapling linkers of the peptides contribute to their binding. Calorimetry revealed that the binding of the "closed" isomers is mostly enthalpy-driven, whereas the "open" photoforms bind to the protein stronger due to their increased binding entropy. The results suggest that conformational dynamics of the protein-peptide complexes may explain the differences in the thermodynamic profiles of the binding.
Collapse
Affiliation(s)
- Alexander V Strizhak
- University Chemical Laboratory, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK. and Enamine Ltd, Vul. Chervonotkatska 78, 02094 Kyiv, Ukraine
| | - Oleg Babii
- Institute of Biological Interfaces (IBG-2), Karlsruhe Institute of Technology (KIT), POB 3640, 76021 Karlsruhe, Germany.
| | - Sergii Afonin
- Institute of Biological Interfaces (IBG-2), Karlsruhe Institute of Technology (KIT), POB 3640, 76021 Karlsruhe, Germany.
| | - Iuliia Bakanovich
- University Chemical Laboratory, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK. and Enamine Ltd, Vul. Chervonotkatska 78, 02094 Kyiv, Ukraine
| | - Teodors Pantelejevs
- Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, CB2 1GA Cambridge, UK
| | - Wenshu Xu
- University Chemical Laboratory, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK.
| | - Elaine Fowler
- University Chemical Laboratory, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK.
| | - Rohan Eapen
- Department of Pharmacology, University of Cambridge, Tennis Court Road, CB2 1PD Cambridge, UK
| | - Krishna Sharma
- University Chemical Laboratory, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK.
| | | | - Vasyl V Hurmach
- Enamine Ltd, Vul. Chervonotkatska 78, 02094 Kyiv, Ukraine and Taras Shevchenko National University of Kyiv, Vul. Volodymyrska 60, 01601 Kyiv, Ukraine
| | - Laura Itzhaki
- Department of Pharmacology, University of Cambridge, Tennis Court Road, CB2 1PD Cambridge, UK
| | - Marko Hyvönen
- Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, CB2 1GA Cambridge, UK
| | - Anne S Ulrich
- Institute of Biological Interfaces (IBG-2), Karlsruhe Institute of Technology (KIT), POB 3640, 76021 Karlsruhe, Germany. and Institute of Organic Chemistry (IOC), KIT, Fritz-Haber-Weg 6, 76131 Karlsruhe, Germany
| | - David R Spring
- University Chemical Laboratory, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK.
| | - Igor V Komarov
- Taras Shevchenko National University of Kyiv, Vul. Volodymyrska 60, 01601 Kyiv, Ukraine and Lumobiotics GmbH, Auer Str. 2, 76227, Karlsruhe, Germany.
| |
Collapse
|
18
|
Targeted Cancer Therapy Using Compounds Activated by Light. Cancers (Basel) 2021; 13:cancers13133237. [PMID: 34209493 PMCID: PMC8269035 DOI: 10.3390/cancers13133237] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 06/18/2021] [Accepted: 06/24/2021] [Indexed: 12/21/2022] Open
Abstract
Cancer chemotherapy is affected by a modest selectivity and toxic side effects of pharmacological interventions. Among novel approaches to overcome this limitation and to bring to therapy more potent and selective agents is the use of light for selective activation of anticancer compounds. In this review, we focus on the anticancer applications of two light-activated approaches still in the experimental phase: photoremovable protecting groups ("photocages") and photoswitches. We describe the structural considerations behind the development of novel compounds and the plethora of assays used to confirm whether the photochemical and pharmacological properties are meeting the stringent criteria for an efficient in vivo light-dependent activation. Despite its immense potential, light activation brings many challenges, and the complexity of the task is very demanding. Currently, we are still deeply in the phase of pharmacological tools, but the vivid research and rapid development bring the light of hope for potential clinical use.
Collapse
|
19
|
The Issue of Tissue: Approaches and Challenges to the Light Control of Drug Activity. CHEMPHOTOCHEM 2021; 5:611-618. [DOI: 10.1002/cptc.202100001] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
20
|
Kolarski D, Sugiyama A, Rodat T, Schulte A, Peifer C, Itami K, Hirota T, Feringa BL, Szymanski W. Reductive stability evaluation of 6-azopurine photoswitches for the regulation of CKIα activity and circadian rhythms. Org Biomol Chem 2021; 19:2312-2321. [DOI: 10.1039/d1ob00014d] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
6-Azopurines were evaluated for their reductive stability, and the ability to modulate CKIα activity and cellular circadian rhythms, revealing key challenges for long-term activity modulation utilizing chronophotopharmacology.
Collapse
Affiliation(s)
- Dušan Kolarski
- Stratingh Institute for Chemistry
- University of Groningen
- Groningen
- The Netherlands
| | - Akiko Sugiyama
- Institute of Transformative Bio-Molecules (WPI-ITbM)
- Nagoya University
- Nagoya 464-8601
- Japan
| | - Theo Rodat
- Department of Pharmaceutical and Medicinal Chemistry
- Christian-Albrechts-University of Kiel
- 24118 Kiel
- Germany
| | - Albert Schulte
- Stratingh Institute for Chemistry
- University of Groningen
- Groningen
- The Netherlands
| | - Christian Peifer
- Department of Pharmaceutical and Medicinal Chemistry
- Christian-Albrechts-University of Kiel
- 24118 Kiel
- Germany
| | - Kenichiro Itami
- Institute of Transformative Bio-Molecules (WPI-ITbM)
- Nagoya University
- Nagoya 464-8601
- Japan
| | - Tsuyoshi Hirota
- Institute of Transformative Bio-Molecules (WPI-ITbM)
- Nagoya University
- Nagoya 464-8601
- Japan
| | - Ben L. Feringa
- Stratingh Institute for Chemistry
- University of Groningen
- Groningen
- The Netherlands
| | - Wiktor Szymanski
- Stratingh Institute for Chemistry
- University of Groningen
- Groningen
- The Netherlands
- Medical Imaging Center
| |
Collapse
|
21
|
Sharma V, Rana R, Baksi R, Borse SP, Nivsarkar M. Light-controlled calcium signalling in prostate cancer and benign prostatic hyperplasia. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES 2020. [DOI: 10.1186/s43094-020-00046-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Abstract
Background
Identifying ways to reduce the burden of prostate cancer (Pca) or benign prostatic hyperplasia (BPH) is a top research priority. It is a typical entanglement seen in men which is portrayed by trouble in micturition. It stands as a significant problem in our society. Different molecular biomarker has high potential to treat Pca or BPH but also causes serious side effects during treatment.
Main text
The role of calcium signalling in the alteration of different biomarkers of Pca or BPH is important. Therefore, the photoswitch drugs may hold the potential to rebalance the altered calcium signaling cascade and the biomarker levels. Thereby play a significant role in the management of Pca and BPH. Online literature searches such as PubMed, Web of Science, Scopus, and Google Scholar were carried out. The search terms used for this review were photo-pharmacology, photo-switch drug, photodynamic therapy, calcium signalling, etc. Present treatment of Pca or BPH shows absence of selectivity and explicitness which may additionally result in side effects. The new condition of the calcium flagging may offer promising outcomes in restoring the present issues related with prostate malignancy and BPH treatment.
Conclusion
The light-switching calcium channel blockers aim to solve this issue by incorporating photo-switchable calcium channel blockers that may control the signalling pathway related to proliferation and metastasis in prostate cancer without any side effects.
Graphical abstract
Schematic diagram explaining the proposed role of photo-switch therapy in curbing the side effects of active drugs in Pca (prostate cancer) and BPH (benign prostatic hyperplasia). a) Delivery of medication by ordinary strategies and irreversible phototherapy causes side effects during treatment. Utilization of photo-switch drug to control the dynamic and inert condition of the medication can cause the medication impacts as we required in prostate cancer and BPH. b) Support of harmony between the calcium signaling is essential to guarantee ordinary physiology. Increment or abatement in the dimensions of calcium signaling can result in changed physiology. c) Major factors involved in the pathogenesis of BPH; downregulation of vitamin D receptor (VDR) and histone deacetylase (HDAC) can prevent BPH. Similarly, downregulation of α-1 adrenoceptor can reduce muscle contraction, while overexpression of β-3 adrenoceptor in BPH can promote further muscle relaxation in BPH treatment therapy. Inhibition of overexpressed biomarkers in BPH TRPM2-1: transient receptor potential cation channel subfamily M member 1; TRPM2-2: transient receptor potential cation channel subfamily M member 2; Androgens; CXCL5: C-X-C motif chemokine ligand 5; TGFβ-1: transforming growth factor β-1; TXA2; thromboxane-2; NMDA: N-methyl-d-aspartate can be the potential target in BPH therapy.
Collapse
|
22
|
Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib. Int J Mol Sci 2020; 21:ijms21238961. [PMID: 33255816 PMCID: PMC7734574 DOI: 10.3390/ijms21238961] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 11/21/2020] [Accepted: 11/22/2020] [Indexed: 12/16/2022] Open
Abstract
In this study, we aimed at the application of the concept of photopharmacology to the approved vascular endothelial growth factor receptor (VEGFR)-2 kinase inhibitor axitinib. In a previous study, we found out that the photoisomerization of axitinib’s stilbene-like double bond is unidirectional in aqueous solution due to a competing irreversible [2+2]-cycloaddition. Therefore, we next set out to azologize axitinib by means of incorporating azobenzenes as well as diazocine moieties as photoresponsive elements. Conceptually, diazocines (bridged azobenzenes) show favorable photoswitching properties compared to standard azobenzenes because the thermodynamically stable Z-isomer usually is bioinactive, and back isomerization from the bioactive E-isomer occurs thermally. Here, we report on the development of different sulfur–diazocines and carbon–diazocines attached to the axitinib pharmacophore that allow switching the VEGFR-2 activity reversibly. For the best sulfur–diazocine, we could verify in a VEGFR-2 kinase assay that the Z-isomer is biologically inactive (IC50 >> 10,000 nM), while significant VEGFR-2 inhibition can be observed after irradiation with blue light (405 nm), resulting in an IC50 value of 214 nM. In summary, we could successfully develop reversibly photoswitchable kinase inhibitors that exhibit more than 40-fold differences in biological activities upon irradiation. Moreover, we demonstrate the potential advantage of diazocine photoswitches over standard azobenzenes.
Collapse
|
23
|
Rodat T, Krebs M, Döbber A, Jansen B, Steffen-Heins A, Schwarz K, Peifer C. Restricted suitability of BODIPY for caging in biological applications based on singlet oxygen generation. Photochem Photobiol Sci 2020; 19:1319-1325. [PMID: 32820789 DOI: 10.1039/d0pp00097c] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Recent studies report the boron-dipyrromethene (BODIPY) moiety to be interesting for caging applications in photopharmacology based on its response to irradiation with wavelengths in the biooptical window. Thus, in a model study, we investigated the meso-methyl-BODIPY caged CDK2 inhibitor AZD5438 and aimed to assess the usability of BODIPY as a photoremovable protecting group in photoresponsive kinase inhibitor applications. Photochemical analysis and biological characterisation in vitro revealed significant limitations of the BODIPY-caged inhibitor concept regarding solubility and uncaging in aqueous solution. Notably, we provide evidence for BODIPY-caged compounds generating singlet oxygen/radicals upon irradiation, followed by photodegradation of the caged compound system. Consequently, instead of caging, a non-specific induction of necrosis in cells suggests the potential usage of BODIPY derivatives for photodynamic approaches.
Collapse
Affiliation(s)
- Theo Rodat
- Institute of Pharmacy, Kiel University, Gutenbergstraße 76, 24118 Kiel, Germany.
| | - Melanie Krebs
- Institute of Pharmacy, Kiel University, Gutenbergstraße 76, 24118 Kiel, Germany.
| | - Alexander Döbber
- Institute of Pharmacy, Kiel University, Gutenbergstraße 76, 24118 Kiel, Germany.
| | - Björn Jansen
- Institute of Pharmacy, Kiel University, Gutenbergstraße 76, 24118 Kiel, Germany.
| | - Anja Steffen-Heins
- Institute of Human Nutrition and Food Science, Division of Food Technology, Kiel University, Heinrich-Hecht-Platz 10, 24118 Kiel, Germany
| | - Karin Schwarz
- Institute of Human Nutrition and Food Science, Division of Food Technology, Kiel University, Heinrich-Hecht-Platz 10, 24118 Kiel, Germany
| | - Christian Peifer
- Institute of Pharmacy, Kiel University, Gutenbergstraße 76, 24118 Kiel, Germany.
| |
Collapse
|
24
|
Kölsch S, Ihmels H, Mattay J, Sewald N, Patrick BO. Reversible photoswitching of the DNA-binding properties of styrylquinolizinium derivatives through photochromic [2 + 2] cycloaddition and cycloreversion. Beilstein J Org Chem 2020; 16:111-124. [PMID: 32082430 PMCID: PMC7006495 DOI: 10.3762/bjoc.16.13] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Accepted: 01/08/2020] [Indexed: 12/17/2022] Open
Abstract
It was demonstrated that styrylquinolizinium derivatives may be applied as photoswitchable DNA ligands. At lower ligand:DNA ratios (≤1.5), these compounds bind to duplex DNA by intercalation, with binding constants ranging from K b = 4.1 × 104 M to 2.6 × 105 M (four examples), as shown by photometric and fluorimetric titrations as well as by CD and LD spectroscopic analyses. Upon irradiation at 450 nm, the methoxy-substituted styrylquinolizinium derivatives form the corresponding syn head-to-tail cyclobutanes in a selective [2 + 2] photocycloaddition, as revealed by X-ray diffraction analysis of the reaction products. These photodimers bind to DNA only weakly by outside-edge association, but they release the intercalating monomers upon irradiation at 315 nm in the presence of DNA. As a result, it is possible to switch between these two ligands and likewise between two different binding modes by irradiation with different excitation wavelengths.
Collapse
Affiliation(s)
- Sarah Kölsch
- Department of Chemistry and Biology, Organic Chemistry II, University of Siegen, Adolf-Reichwein-Str. 2, D-57068 Siegen, Germany
| | - Heiko Ihmels
- Department of Chemistry and Biology, Organic Chemistry II, University of Siegen, Adolf-Reichwein-Str. 2, D-57068 Siegen, Germany
| | - Jochen Mattay
- Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, PO Box 100121, D-33501 Bielefeld, Germany
| | - Norbert Sewald
- Department of Chemistry, Organic and Bioorganic Chemistry, Bielefeld University, PO Box 100121, D-33501 Bielefeld, Germany
| | - Brian O Patrick
- Department of Chemistry, Structural Chemistry Facility, The University of British Columbia, 2036 Main Mall, V6T 1Z1, Vancouver, BC, Canada
| |
Collapse
|
25
|
Demchuk OP, Hryshchuk OV, Vashchenko BV, Radchenko DS, Kovtunenko VO, Komarov IV, Grygorenko OO. Robust and Scalable Approach to 1,3-Disubstituted Pyridylcyclobutanes. European J Org Chem 2019. [DOI: 10.1002/ejoc.201901001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Oleksandr P. Demchuk
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- Taras Shevchenko National University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | - Oleksandr V. Hryshchuk
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- Taras Shevchenko National University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | - Bohdan V. Vashchenko
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- Taras Shevchenko National University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | - Dmytro S. Radchenko
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- Taras Shevchenko National University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | | | - Igor V. Komarov
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- Taras Shevchenko National University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| | - Oleksandr O. Grygorenko
- Enamine Ltd.; Chervonotkatska Street 78 02094 Kyiv Ukraine
- Taras Shevchenko National University of Kyiv; Volodymyrska Street 60 01601 Kyiv Ukraine
| |
Collapse
|
26
|
Hoorens MWH, Ourailidou ME, Rodat T, van der Wouden PE, Kobauri P, Kriegs M, Peifer C, Feringa BL, Dekker FJ, Szymanski W. Light-controlled inhibition of BRAFV600E kinase. Eur J Med Chem 2019; 179:133-146. [PMID: 31252305 DOI: 10.1016/j.ejmech.2019.06.042] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Revised: 05/22/2019] [Accepted: 06/15/2019] [Indexed: 11/26/2022]
Abstract
Metastatic melanoma is amongst the most difficult types of cancer to treat, with current therapies mainly relying on the inhibition of the BRAFV600E mutant kinase. However, systemic inhibition of BRAF by small molecule drugs in cancer patients results - paradoxically - in increased wild-type BRAF activity in healthy tissue, causing side-effects and even the formation of new tumors. Here we show the development of BRAFV600E kinase inhibitors of which the activity can be switched on and off reversibly with light, offering the possibility to overcome problems of systemic drug activity by selectively activating the drug at the desired site of action. Based on a known inhibitor, eight photoswitchable effectors containing an azobenzene photoswitch were designed, synthesized and evaluated. The most promising inhibitor showed an approximately 10-fold increase in activity upon light-activation. This research offers inspiration for the development of therapies for metastatic melanoma in which tumor tissue is treated with an active BRAFV600E inhibitor with high spatial and temporal resolution, thus limiting the damage to other tissues.
Collapse
Affiliation(s)
- Mark W H Hoorens
- University Medical Center Groningen, Department of Radiology, Medical Imaging Center, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands; Stratingh Institute for Chemistry, Faculty of Science and Engineering, University of Groningen, Nijenborgh 7, 9747 AG Groningen, Netherlands
| | - Maria E Ourailidou
- Department of Chemical and Pharmaceutical Biology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, Netherlands
| | - Theo Rodat
- Institute of Pharmacy, Christian-Albrechts-University of Kiel, Gutenbergstr. 76, 24118 Kiel, Germany
| | - Petra E van der Wouden
- Department of Chemical and Pharmaceutical Biology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, Netherlands
| | - Piermichele Kobauri
- Stratingh Institute for Chemistry, Faculty of Science and Engineering, University of Groningen, Nijenborgh 7, 9747 AG Groningen, Netherlands
| | - Malte Kriegs
- Laboratory of Radiobiology & Experimental Radiooncology and UCCH Kinomics Core Facility, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
| | - Christian Peifer
- Institute of Pharmacy, Christian-Albrechts-University of Kiel, Gutenbergstr. 76, 24118 Kiel, Germany
| | - Ben L Feringa
- Stratingh Institute for Chemistry, Faculty of Science and Engineering, University of Groningen, Nijenborgh 7, 9747 AG Groningen, Netherlands
| | - Frank J Dekker
- Department of Chemical and Pharmaceutical Biology, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, Netherlands
| | - Wiktor Szymanski
- University Medical Center Groningen, Department of Radiology, Medical Imaging Center, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands; Stratingh Institute for Chemistry, Faculty of Science and Engineering, University of Groningen, Nijenborgh 7, 9747 AG Groningen, Netherlands.
| |
Collapse
|
27
|
Sailer A, Ermer F, Kraus Y, Lutter FH, Donau C, Bremerich M, Ahlfeld J, Thorn‐Seshold O. Hemithioindigos for Cellular Photopharmacology: Desymmetrised Molecular Switch Scaffolds Enabling Design Control over the Isomer‐Dependency of Potent Antimitotic Bioactivity. Chembiochem 2019; 20:1305-1314. [DOI: 10.1002/cbic.201800752] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Indexed: 01/28/2023]
Affiliation(s)
- Alexander Sailer
- Department of PharmacyLudwig-Maximilians University Munich Butenandtstrasse 5–13 Munich 81377 Germany
| | - Franziska Ermer
- Department of PharmacyLudwig-Maximilians University Munich Butenandtstrasse 5–13 Munich 81377 Germany
| | - Yvonne Kraus
- Department of PharmacyLudwig-Maximilians University Munich Butenandtstrasse 5–13 Munich 81377 Germany
| | - Ferdinand H. Lutter
- Department of PharmacyLudwig-Maximilians University Munich Butenandtstrasse 5–13 Munich 81377 Germany
| | - Carsten Donau
- Department of PharmacyLudwig-Maximilians University Munich Butenandtstrasse 5–13 Munich 81377 Germany
| | - Maximilian Bremerich
- Department of PharmacyLudwig-Maximilians University Munich Butenandtstrasse 5–13 Munich 81377 Germany
| | - Julia Ahlfeld
- Department of PharmacyLudwig-Maximilians University Munich Butenandtstrasse 5–13 Munich 81377 Germany
| | - Oliver Thorn‐Seshold
- Department of PharmacyLudwig-Maximilians University Munich Butenandtstrasse 5–13 Munich 81377 Germany
| |
Collapse
|
28
|
Fleming CL, Grøtli M, Andréasson J. On‐Command Regulation of Kinase Activity using Photonic Stimuli. CHEMPHOTOCHEM 2019. [DOI: 10.1002/cptc.201800253] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Cassandra L. Fleming
- Department of Chemistry and Molecular BiologyUniversity of Gothenburg SE-41296 Göteborg Sweden
| | - Morten Grøtli
- Department of Chemistry and Molecular BiologyUniversity of Gothenburg SE-41296 Göteborg Sweden
| | - Joakim Andréasson
- Department of Chemistry and Chemical Engineering, Chemistry and BiochemistryChalmers University of Technology SE-41296 Göteborg Sweden
| |
Collapse
|
29
|
Sõrmus T, Lavogina D, Enkvist E, Uri A, Viht K. Efficient photocaging of a tight-binding bisubstrate inhibitor of cAMP-dependent protein kinase. Chem Commun (Camb) 2019; 55:11147-11150. [DOI: 10.1039/c9cc04978a] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
PKA bisubstrate inhibitor photocaging resulted in an over 5 orders of magnitude affinity difference between the photocaged and the active inhibitor.
Collapse
Affiliation(s)
- Tanel Sõrmus
- Institute of Chemistry
- University of Tartu
- 50411 Tartu
- Estonia
| | - Darja Lavogina
- Institute of Chemistry
- University of Tartu
- 50411 Tartu
- Estonia
| | - Erki Enkvist
- Institute of Chemistry
- University of Tartu
- 50411 Tartu
- Estonia
| | - Asko Uri
- Institute of Chemistry
- University of Tartu
- 50411 Tartu
- Estonia
| | - Kaido Viht
- Institute of Chemistry
- University of Tartu
- 50411 Tartu
- Estonia
| |
Collapse
|